https://www.selleckchem.com/pr....oducts/vacuolin-1.ht
P2Y inhibitor monotherapy following short-term DAPT (1 to 3months) significantly reduced the risk of BARC type 3 or 5 bleeding compared to standard DAPT (pooled HR 0.63, 95%CI 0.46-0.86). The difference between P2Y inhibitor monotherapy and standard DAPT in reducing the composite CVD outcomes was not statistically significant (HR 0.88, 95%CI 0.77-1.01). P2Y inhibitor monotherapy might be an effective strategy for lowering severe bleeding complications and simultaneously preserving the ischemic benefit in patients receiving PCI. P2Y12
Like
Comment
Share
